Stay updated on Autologous DCs+Tumor Lysate+Nivolumab in Recurrent Glioblastoma Clinical Trial
Sign up to get notified when there's something new on the Autologous DCs+Tumor Lysate+Nivolumab in Recurrent Glioblastoma Clinical Trial page.

Latest updates to the Autologous DCs+Tumor Lysate+Nivolumab in Recurrent Glioblastoma Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedLocations section updated to include California. The California Locations header was removed, the HHS Vulnerability Disclosure link was removed from the footer, and the revision tag updated from v3.3.2 to v3.3.3.SummaryDifference0.2%

- Check21 days agoNo Change Detected
- Check28 days agoNo Change Detected
- Check42 days agoChange DetectedRevision label updated from v3.2.0 to v3.3.2. No substantive study information appears to be affected.SummaryDifference0.1%

- Check50 days agoChange DetectedThe funding-status notice banner was removed from the page. It previously warned about potential delays and pointed to NIH and government updates for status information.SummaryDifference0.4%

- Check71 days agoChange DetectedNo significant additions or deletions were detected on the page; the study details and eligibility criteria appear unchanged.SummaryDifference0.4%

- Check93 days agoChange DetectedMajor update: announces a version upgrade to v3.2.0 and publicly states funding-related operational notices, including that transactions may not be processed until appropriations are enacted.SummaryDifference3%

- Check100 days agoChange DetectedThe page update adds the new version tag v3.1.0 and removes the old v3.0.2 tag, signaling a software version upgrade.SummaryDifference0.1%

Stay in the know with updates to Autologous DCs+Tumor Lysate+Nivolumab in Recurrent Glioblastoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Autologous DCs+Tumor Lysate+Nivolumab in Recurrent Glioblastoma Clinical Trial page.